Clinical Trial Update: Safety and Antiviral Study of ACH-126, 443 (Beta-L-Fd4C) in the Treatment of Adults With HIV Infection and Modestly Detectable Viral Load. [Phase 2]

View source ↗

Summary

A Phase 2 safety and antiviral study of ACH-126, 443 (Beta-L-Fd4C) in adults with HIV infection and modestly detectable viral load has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• ACH-126, 443 (Beta-L-Fd4C)

Snippet

Sponsor: Alexion Pharmaceuticals, Inc. | Conditions: HIV Infections | Phase 2 | Status: TERMINATED